The inflammatory burden index is a superior systemic inflammation biomarker for the prognosis of non-small cell lung cancer.

ABSTRACT:

Background

Systemic inflammation, the most representative tumour-host interaction, plays a crucial role in disease progression and prognosis in patients with non-small cell lung cancer (NSCLC). Few studies have compared the performance of existing haematological systemic inflammation biomarkers in predicting the prognosis of NSCLC patients. The purpose of this study was to compare the prognostic value of existing systemic inflammation biomarkers and determine the optimal systemic inflammation biomarker in patients with NSCLC through a multicentre prospective study.

Methods

The predictive accuracy of systemic inflammation biomarkers for prognostic assessment in NSCLC was assessed using C-statistics. Inter-group differences in survival were assessed using the log-rank test and

SUBMITTER: Xie H 

PROVIDER: S-EPMC10067487 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature